Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. The company's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A. In addition, its product candidates and development programs include SPK-FVIII program to treat hemophilia A; SPK-TPP1 program for the treatment of CLN2 disease; RhoNova for the treatment of rhodopsin-linked autosomal dominant retinitis pigmentosa; and other neurodegenerative diseases. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone888-772-7560
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$12.07 million
Profitability
Miscellaneous
Employees315
OptionableOptionable
Spark Therapeutics (NASDAQ:ONCE) Frequently Asked Questions
What is Spark Therapeutics' stock symbol?
Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."
How were Spark Therapeutics' earnings last quarter?
Spark Therapeutics Inc (NASDAQ:ONCE) issued its quarterly earnings results on Tuesday, November, 6th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.04) by $0.22. The biotechnology company earned $10.70 million during the quarter, compared to analyst estimates of $27.44 million. Spark Therapeutics had a negative return on equity of 14.18% and a negative net margin of 127.82%. The business's revenue was up 463.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.90) earnings per share. View Spark Therapeutics' Earnings History.
When is Spark Therapeutics' next earnings date?
What price target have analysts set for ONCE?
20 equities research analysts have issued 1 year price objectives for Spark Therapeutics' stock. Their forecasts range from $40.00 to $85.00. On average, they expect Spark Therapeutics' share price to reach $65.7895 in the next year. This suggests a possible upside of 45.9% from the stock's current price. View Analyst Price Targets for Spark Therapeutics.
What is the consensus analysts' recommendation for Spark Therapeutics?
20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spark Therapeutics in the last year. There are currently 8 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Spark Therapeutics.
What are Wall Street analysts saying about Spark Therapeutics stock?
Here are some recent quotes from research analysts about Spark Therapeutics stock:
- 1. According to Zacks Investment Research, "Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. " (1/9/2019)
- 2. JPMorgan Chase & Co. analysts commented, "ONCE’s 3Q print encouragingly showed in line Luxturna sales of ~$9M, although a resetting of expectations around the SPK-8011 update at ASH overshadowed launch progress. Given the historical focus on FVIII levels, we aren’t surprised to see disappointment about the news that there will be no biomarker data for the high dose cohort at ASH (there will be clinical outcome data). Indeed, for some time we’ve gotten the sense that at least some investors may wait to see additional SPK-8011 FVIII activity data before re-engaging. That said, today’s update doesn’t fundamentally change the fact that ONCE continues to be a leader in the gene therapy space, with an active early-stage pipeline (2 new programs entering clinic in late- 2018/2019) and an update on SPK-7001 expected by YE18. Maintain Neutral." (11/7/2018)
- 3. Raymond James analysts commented, "We are maintaining our Outperform rating for shares of ONCE. This morning the E.U.’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of LUXTURNA for the treatment of vision loss due to inherited retinal dystrophy (IRD) caused by mutations in the retinal pigment epithelium- specific 65 kDa (RPE65) gene. Along with robust data from the company’s Phase III study that demonstrated safety, efficacy, and durability of response for up to three years, the company awaits a marketing authorization from the European Commission within two months to become the first gene therapy for a genetic disease approved in both the U.S. and E.U. With U.S." (9/21/2018)
- 4. Mizuho analysts commented, "We further think it is pre-mature to draw the conclusion that SPK-8011 is inferior to the competing product from BioMarin (BMRN, non-rated). We reduce our PT from $91 to $77 after removing the M&A premium of our valuation per revised valuation methodology and we maintain our revenue forecasts." (8/8/2018)
- 5. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and 12-month PT of $103 on 2Q18 financial results and program updates. During the call, Spark announced additional updates from the Phase 1/2 trial of SPK-8011 in hemophilia A. While the occurrence of two immune responses leading to inadequate FVIII activity level add challenges for the program, we believe the company is well equipped to address them as the program moves to late-stage development." (8/7/2018)
Has Spark Therapeutics been receiving favorable news coverage?
News coverage about ONCE stock has trended somewhat positive on Saturday, InfoTrie reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Spark Therapeutics earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the company's share price in the near term.
Who are some of Spark Therapeutics' key competitors?
Some companies that are related to Spark Therapeutics include BIO-TECHNE (TECH), Ablynx (ABLYF), Allogene Therapeutics (ALLO), argenx (ARGX), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA), Regenxbio (RGNX), Editas Medicine (EDIT) and Autolus Therapeutics (AUTL).
Who are Spark Therapeutics' key executives?
Spark Therapeutics' management team includes the folowing people:
- Mr. Jeffrey D. Marrazzo, Co-Founder, CEO & Director (Age 40)
- Dr. Katherine A. High, Co-Founder, Pres, Head of R&D and Director (Age 67)
- Mr. Stephen W. Webster, Chief Financial Officer (Age 58)
- Mr. Joseph W. La Barge Esq., J.D., Chief Legal Officer & Sec. (Age 48)
- Mr. Daniel R. Faga, Chief Bus. Officer (Age 39)
When did Spark Therapeutics IPO?
(ONCE) raised $88 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 5,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.
How do I buy shares of Spark Therapeutics?
Shares of ONCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spark Therapeutics' stock price today?
One share of ONCE stock can currently be purchased for approximately $45.08.
How big of a company is Spark Therapeutics?
Spark Therapeutics has a market capitalization of $1.64 billion and generates $12.07 million in revenue each year. The biotechnology company earns $-253,480,000.00 in net income (profit) each year or ($7.63) on an earnings per share basis. Spark Therapeutics employs 315 workers across the globe.
What is Spark Therapeutics' official website?
How can I contact Spark Therapeutics?
Spark Therapeutics' mailing address is 3737 Market Street Suite 1300, PHILADELPHIA PA, 19104. The biotechnology company can be reached via phone at 888-772-7560 or via email at [email protected]
MarketBeat Community Rating for Spark Therapeutics (NASDAQ ONCE)
MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Vote "Outperform" if you believe ONCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
